News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ALK-Abello A/S's Partner For North America, Merck & Co., Inc. (MRK), Announces Launch Of RAGWITEK™ In Canada



5/15/2014 11:53:45 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Copenhagen, 2014-05-15 13:00 CEST (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its ragweed sublingual allergy immunotherapy tablet, which is licensed to Merck (known as MSD outside the USA and Canada) for North America, has now been launched in Canada. - See more at: http://www.globenewswire.com/news-release/2014/05/15/636727/0/en/ALK-s-partner-for-North-America-Merck-announces-launch-of-RAGWITEK-in-Canada.html#sthash.Wo5fPgJE.dpuf

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES